| Mark Hazem Sahlol, | |
|
24 Joliet St, Dyer, IN 46311-1705 | |
| (219) 865-2141 | |
| (219) 852-2502 |
| Full Name | Mark Hazem Sahlol |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 18 Years |
| Location | 24 Joliet St, Dyer, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184930604 | NPI | - | NPPES |
| 201292580 | Medicaid | IN |
| Facility Name | Location | Facility Type |
|---|---|---|
| Franciscan Health Munster | Munster, IN | Hospital |
| Franciscan Health Dyer | Dyer, IN | Hospital |
| Franciscan Health Crown Point | Crown point, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Franciscan Physician Network | 3072790682 | 989 |
News Archive
In this post in KPLU 88.5's "Humanosphere" blog, journalist Tom Murphy interviews reporter Jonathan Katz, "the first to break the story connecting U.N. peacekeepers from Nepal to the" cholera outbreak in Haiti.
QIAGEN today announced the formation of its India subsidiary, QIAGEN India Pvt. Ltd., and the beginning of direct sales in the country. Until now, QIAGEN products have been sold in India through distributor partnerships.
In the first survey to specifically measure hospital pediatric preparedness, a team of Los Angeles Biomedical Research Institute (LA BioMed) researchers found few U.S. emergency rooms are properly equipped for children.
Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation.
› Verified 5 days ago
| Entity Name | Parkview Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932130952 PECOS PAC ID: 2163336967 Enrollment ID: O20031117000288 |
News Archive
In this post in KPLU 88.5's "Humanosphere" blog, journalist Tom Murphy interviews reporter Jonathan Katz, "the first to break the story connecting U.N. peacekeepers from Nepal to the" cholera outbreak in Haiti.
QIAGEN today announced the formation of its India subsidiary, QIAGEN India Pvt. Ltd., and the beginning of direct sales in the country. Until now, QIAGEN products have been sold in India through distributor partnerships.
In the first survey to specifically measure hospital pediatric preparedness, a team of Los Angeles Biomedical Research Institute (LA BioMed) researchers found few U.S. emergency rooms are properly equipped for children.
Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation.
› Verified 5 days ago
| Entity Name | Franciscan Physician Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225327984 PECOS PAC ID: 3072790682 Enrollment ID: O20110608000486 |
News Archive
In this post in KPLU 88.5's "Humanosphere" blog, journalist Tom Murphy interviews reporter Jonathan Katz, "the first to break the story connecting U.N. peacekeepers from Nepal to the" cholera outbreak in Haiti.
QIAGEN today announced the formation of its India subsidiary, QIAGEN India Pvt. Ltd., and the beginning of direct sales in the country. Until now, QIAGEN products have been sold in India through distributor partnerships.
In the first survey to specifically measure hospital pediatric preparedness, a team of Los Angeles Biomedical Research Institute (LA BioMed) researchers found few U.S. emergency rooms are properly equipped for children.
Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Hazem Sahlol, Po Box 781076, Detroit, MI 48278-1076 Ph: (317) 528-4800 | Mark Hazem Sahlol, 24 Joliet St, Dyer, IN 46311-1705 Ph: (219) 865-2141 |
News Archive
In this post in KPLU 88.5's "Humanosphere" blog, journalist Tom Murphy interviews reporter Jonathan Katz, "the first to break the story connecting U.N. peacekeepers from Nepal to the" cholera outbreak in Haiti.
QIAGEN today announced the formation of its India subsidiary, QIAGEN India Pvt. Ltd., and the beginning of direct sales in the country. Until now, QIAGEN products have been sold in India through distributor partnerships.
In the first survey to specifically measure hospital pediatric preparedness, a team of Los Angeles Biomedical Research Institute (LA BioMed) researchers found few U.S. emergency rooms are properly equipped for children.
Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation.
› Verified 5 days ago
Jeannie Boram Ur, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 24 Joliet St, Dyer, IN 46311 Phone: 219-865-2141 Fax: 219-933-2288 | |
Dr. Harold Leroy Rahming, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 24 Joliet St, Dyer, IN 46311 Phone: 219-865-2141 Fax: 219-933-2288 |